An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous R435(bevacizumab) treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy
Phase 4
- Conditions
- non-squamous non-small cell lung cancer
- Registration Number
- JPRN-jRCT1080221719
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Age >= 18 years.
-Sex:Both
-Ability to comply with the protocol.
-Histologically or cytologically confirmed non-squamous NSCLC
-At least 1 unidimensionally measurable lesion meeting RECIST (v.1.1) criteria.
-Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2.
Exclusion Criteria
-Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component.
-EGFR-mutation-positive disease according to local laboratory testing.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method